About seqWell
seqWell is a Healthcare company based in Beverly (United States) founded in 2014 by Jack Leonard. NGS-based reagents and kits are supplied for life sciences research. seqWell has raised $24.51 million across 6 funding rounds from investors including Codexis, Broadoak Capital Partners and Research Corporation Technologies. seqWell offers products and services including ExpressPlex™ 2.0, Tagify™, and purePlex™. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its legal entity is SEQWELL, INC. Its competitors include Neogen, RareCyte and Paragon Genomics; 3 of its 3 listed competitors have raised funding.
Company details
SeqWell was founded in 2014 and is headquartered in Beverly, United States. Reagents and kits based on next-generation sequencing (NGS) technology are provided for life sciences research applications. The plexWell platform has been developed to support parallelized library preparation, enabling multiplexing of hundreds to thousands of samples. This Illumina-compatible technology facilitates increased sample throughput on benchtop NGS instruments. Operations focus on simplifying sample preparation processes in the biotechnology sector.
- Total Equity Funding$24.51M (USD)
in 6 rounds
- Latest Funding Round$3.12M (USD), Series C
Sep 2024
- InvestorsCodexis
& 3 more
Products & Services of seqWell
seqWell offers a comprehensive portfolio of products and services, including ExpressPlex™ 2.0, Tagify™, and purePlex™.
Enables quick NGS library preparation with multiplexing for research.
Provides custom-loaded transposase for efficient genomic workflows.
Offers auto-normalization for streamlined sequencing sample processing.
Apps and channels of seqWell
its YouTube channel seqWell has 61 subscribers and 21 videos.
Videos from seqWell
The most watched videos on seqWell's YouTube channel, seqWell (61 subscribers). Click a video to play it here.
More on seqWell.
Funding Insights of seqWell
seqWell has successfully raised a total of $24.51M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $3.12 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.51M
- Total Rounds 6
- Last Round Series C — $3.12M
- First Round $1.29M
(Jul 2016)
- Investors Count 4
All 6 funding rounds of seqWell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
4 investors in total: 4 institutional.
Investors in seqWell
seqWell has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Codexis, Broadoak Capital Partners and Research Corporation Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research Corporation Technologies is engaged in licensing biomedical technologies. | rctech.com | Tucson, United States | ||
High-performance enzymes are developed for drug discovery and biotherapeutics. | 2002 | codexis.com | Redwood City, United States | |
Investment banking services are offered in the United States. | 2006 | broadoak.com | Bethesda, United States | |
| currentinvestors.com |
Investor details for seqWell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of seqWell
30 people are tracked at seqWell (9 in leadership, 7 in board & advisors, 14 in team).
| Name | Role | Group |
|---|---|---|
Jack Leonard | Co-Founder & CTO | Leadership |
Dan Calvo | President & CEO | Leadership |
Maura Costello | Senior Director Of R&d | Leadership |
Keven Stevens | VP Of Sales | Leadership |
Tom Grant | CFO | Leadership |
Michael Finney | Director | Leadership |
Gavin Rush | VP of R&D | Leadership |
Roger Schaller | Vice President Of Business Development | Leadership |
Sabina Gude | Director - Customer Experience And Product Management | Leadership |
Paul Mcewan | Chairman | Board & advisors |
Jason Buenrostro | Scientific Advisor | Board & advisors |
Maryke Appel | Scientific Advisor | Board & advisors |
Chad Souvignier | Board Member | Board & advisors |
Simone Picelli | Scientific Advisor | Board & advisors |
Mike Finney | Board Member | Board & advisors |
Amy Liao | Board Member | Board & advisors |
Zac Zwirko | Team Lead- NGS R&d | Team |
Victoria Thornburg | Office Manager | Team |
Jacquelyn Wilson | Senior Project Manager | Team |
David Bays | Senior Scientist | Team |
10 more people are available in the full profile.
Complete people profiles for seqWell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of seqWell
3 dated milestones of seqWell across 10 years, from founding to its latest funding, stage changes and deals.
- Founded seqWell is founded.
- Funding First funding round of $1.3M.
- Funding Latest funding round, Series C, of $3.1M.
Competitors of seqWell
seqWell has 3 listed competitors in our database, 3 of them funded. They include Neogen, RareCyte and Paragon Genomics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neogen.com | 1982 | Lansing, United States | $700,000 | 2,640 | Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| paragongenomics.com | 2015 | San Francisco, United States | $8M | 26 | Provider of technologies and solutions genomic research and precision medicine |
Detailed competitors of seqWell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of seqWell
The website of seqWell (seqwell.com) receives about 7.4K visits a month.
- Monthly visits7.4K
▼ 1.1% vs previous month
Websites whose visitors overlap most with seqWell. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
gqinnovationcenter.com | gqinnovationcenter.com | 100% | – | ||
| rna-seqblog.com | 99% | #669,184 | View details | ||
| diagenode.com | 84% | 19.4K | #1,415,645 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as seqWell (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Seqwell
Complete news archive for seqWell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about seqWell
seqWell was founded in 2014 and raised its 1st funding round 2 years after it was founded.
seqWell is headquartered in Beverly, United States. It is registered at Beverly, Massachusetts, United States.
seqWell is a funded company, having raised a total of $24.51M across 6 funding rounds to date. The company's 1st funding round was a Seed of $1.29M, raised on Jul 2016.
SeqWell was founded in 2014 and is headquartered in Beverly, United States. Reagents and kits based on next-generation sequencing (NGS) technology are provided for life sciences research applications. The plexWell platform has been developed to support parallelized library preparation, enabling multiplexing of hundreds to thousands of samples. This Illumina-compatible technology facilitates increased sample throughput on benchtop NGS instruments. Operations focus on simplifying sample preparation processes in the biotechnology sector.
seqWell's top competitors include Neogen, Paragon Genomics and RareCyte.
seqWell offers ExpressPlex™ 2.0, Tagify™, and purePlex™.
seqWell has 4 investors. Key investors include Codexis, Broadoak Capital Partners, Research Corporation Technologies, and Current Investors.
seqWell operates through Seqwell, Inc..